Vermillion Releases Initial Results from Vasclir Intended Use Study
October 07, 2011
Vermillion Releases Initial Results from Vasclir Intended Use Study
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Vermillion Posts 11 Percent Rise in 2012 Revenues, 8 Percent Uptick in OVA1 Sales
February 22, 2013 / ProteoMonitor - Vermillion Reports Flat Q3 Revenues, First Peer-Reviewed Publication on Vasclir PAD Test
November 16, 2012 / ProteoMonitor - UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
October 19, 2012 / ProteoMonitor - Vermillion's Q1 Revenues Decline 28 Percent, CEO Page Stepping Down
May 18, 2012 / ProteoMonitor - Vermillion Planning Layoffs, Seeking New Partnerships in 2012
January 6, 2012 / ProteoMonitor